Evidence map›Paper›PMID 25670364›Full record

Trial reportJournal of clinical lipidology

Elevated interleukin-10: a new cause of dyslipidemia leading to severe HDL deficiency.

Andreas G Moraitis, Lita A Freeman, Robert D Shamburek, Robert Wesley, Wyndham Wilson, Cliona M Grant, Susan Price, Stephen Demosky, Seth G Thacker, Abdalrahman Zarzour and 10 more

Abstract readCase ReportsRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical lipidology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. COVID-19-Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  15. Interleukin 10 promotes macrophage uptake of HDL and LDL by stimulating fluid-phase endocytosis.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 3 countries.

Andreas G MoraitisMetabolism, Endocrinology & Diabetes, Endocrine Oncology Program, University of Michigan, Ann Arbor, MI, USA.
Lita A FreemanCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Robert D ShamburekCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Robert WesleyHospital Epidemiology, National Institutes of Health, Bethesda, MD, USA.
Wyndham WilsonNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cliona M GrantNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Susan PriceALPS Unit, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Stephen DemoskyCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Seth G ThackerCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Abdalrahman ZarzourCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Ronald L HornungClinical Services Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Frank PucinoNational Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Gyorgy CsakoDepartment of Laboratory Medicine, National Institutes of Health, Bethesda, MD, USA.
Cheryl YarboroNational Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Iain B McInnesNational Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, Scotland.
Takashi KuroiwaNational Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Dimitrios BoumpasNational Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA; Medical School University of Athens, Affiliate Member IMBB, Heraklion and BRFAA Athens, Greece.
V Koneti RaoALPS Unit, Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Gabor G IlleiNational Institutes of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.
Alan T RemaleyCardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA; Department of Laboratory Medicine, National Institutes of Health, Bethesda, MD, USA. Electronic address: aremaley1@cc.nih.gov.
National Institutes of Health · USNational Institute of Arthritis and Musculoskeletal and Skin Diseases · USNational Cancer Institute · USNational Heart Lung and Blood Institute · USFrederick National Laboratory for Cancer Research · USNational Institute of Allergy and Infectious Diseases · USUniversity of Michigan–Ann Arbor · US

Funding

Clinical, Immunological and Genetic Analyses of ALPS and Related Immunedysregulatory DisordersZIAAI000732 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAO, V KONETI · 2009 to 2025
$10.5M
Development Of New Assays For Lipoprotein TestingZIACL010303 · CLC · CLINICAL CENTER · PI REMALEY, ALAN THOMAS · 2009 to 2017
$0k
CCR NIH HHS HHSN261200800001CIntramural NIH HHS Z99 AI999999Intramural NIH HHS Z99 CA999999Intramural NIH HHS Z99 DE999999Intramural NIH HHS Z99 HL999999NCI NIH HHS HHSN261200800001EPHS HHS HHSN261200800001
6 · The paper itself

Abstract

backgroundLow high-density lipoprotein cholesterol (HDL-C) is a risk factor for coronary artery disease. Investigating mechanisms underlying acquired severe HDL deficiency in noncritically ill patients ("disappearing HDL syndrome") could provide new insights into HDL metabolism.

objectiveTo determine the cause of low HDL-C in patients with severe acquired HDL deficiency. METHODS AND

resultsPatients with intravascular large B-cell lymphoma (n = 2), diffuse large B-cell lymphoma (n = 1), and autoimmune lymphoproliferative syndrome (n = 1) presenting with markedly decreased HDL-C, low low-density lipoprotein cholesterol (LDL-C), and elevated triglycerides were identified. The abnormal lipoprotein profile returned to normal after therapy in all 4 patients. All patients were found to have markedly elevated serum interleukin-10 (IL-10) levels that also normalized after therapy. In a cohort of autoimmune lymphoproliferative syndrome patients (n = 93), IL-10 showed a strong inverse correlation with HDL-C (R(2) = 0.3720, P < .0001). A direct causal role for increased serum IL-10 in inducing the observed changes in lipoproteins was established in a randomized, placebo-controlled clinical trial of recombinant human IL-10 in psoriatic arthritis patients (n = 18). Within a week of initiating subcutaneous recombinant human IL-10 injections, HDL-C precipitously decreased to near-undetectable levels. LDL-C also decreased by more than 50% (P < .0001) and triglycerides increased by approximately 2-fold (P < .005). All values returned to baseline after discontinuing IL-10 therapy.

conclusionIncreased IL-10 causes severe HDL-C deficiency, low LDL-C, and elevated triglycerides. IL-10 is thus a potent modulator of lipoprotein levels, a potential new biomarker for B-cell disorders, and a novel cause of disappearing HDL syndrome.

Indexed as

AdultArthritis, PsoriaticAutoimmune Lymphoproliferative SyndromeChildCholesterol, HDLCholesterol, LDLCohort StudiesDyslipidemiasEnzyme-Linked Immunosorbent Assayfas ReceptorFemaleHumansInfantInterleukin-10Lymphoma, B-CellLymphoma, Large B-Cell, DiffuseCholesterol, HDLCholesterol, LDLFAS protein, humanfas ReceptorInterleukin-10Recombinant ProteinsTriglyceridesALPSB-cell lymphoma“Disappearing HDL syndrome”DyslipidemiaHypertriglyceridemiaIL-10Intravascular large B-cell lymphomaLCATPsoriasisSevere HDL deficiency

Identifiers

PMID25670364
PMCPMC5513489
OpenAlexW2034783317

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.